MDS
MDS
Advertisement
Andrew MorenoMDS | June 14, 2024
This noninvasive technique is a potential improvement over bone marrow aspiration in MDS clinical evaluation and monitoring.
Read More
Heme Today Staff WritersAnemia | February 26, 2024
This would be the fourth authorized indication for luspatercept in the European Union.
Hana Safah, MDMDS | February 8, 2024
The panel shares their outlook for the future of MDS research and treatment.
Hana Safah, MDMDS | February 8, 2024
Dr. Tanaka outlines a biomarker study that observed reduced inflammation in patients with MDS treated with luspatercept.
Hana Safah, MDMDS | February 8, 2024
The panel discussed a study that assessed quality of life and PROs in patients receiving luspatercept for MDS.
Hana Safah, MDMDS | February 8, 2024
The panel discusses whether starting treatment with luspatercept sooner in patients with MDS is beneficial.
Hana Safah, MDMDS | February 8, 2024
Dr. Shammo shares her reaction to a study that assessed mutational burden and impact on primary outcomes in COMMANDS.
Hana Safah, MDMDS | February 8, 2024
Dr. Safah outlines the findings from the full analysis of the COMMANDS trial.
Hana Safah, MDMDS | February 8, 2024
The panel discusses the evolution of MDS therapy and how the MEDALIST trial set the stage for luspatercept.
Hana Safah, MDMDS | February 8, 2024
Dr. Safah gave an overview of myelodysplastic syndromes.
Guillermo Garcia-Manero, MDMDS | February 8, 2024
The panel discusses forward-looking thoughts for the treatment of low-risk MDS.
Guillermo Garcia-Manero, MDMDS | February 8, 2024
The panel talks about the use of transplant for patients with low-risk myelodysplastic syndromes.
Guillermo Garcia-Manero, MDMDS | February 8, 2024
The panel discusses other treatments undergoing research for MDS, including imetelstat and KER-050.
Guillermo Garcia-Manero, MDMDS | February 8, 2024
The panel shared their thoughts on real-world data of luspatercept presented at ASH 2023.
Guillermo Garcia-Manero, MDMDS | February 8, 2024
The panel addresses continued MDS research needs.
Guillermo Garcia-Manero, MDMDS | February 8, 2024
The panel discusses appropriate treatment selection based on patient mutation status and comorbidities.
Guillermo Garcia-Manero, MDMDS | February 8, 2024
The panel shares their thoughts on the full analysis of the COMMANDS study.
DocWire News EditorsMDS | February 8, 2024
The panel discussed the current slate of treatment options for patients with low-risk MDS.
Patrick DalyThrombosis | November 8, 2023
Splenomegaly and myeloproliferative disorders increased risk for porto-spleno-mesenteric venous thrombosis after splenectomy.
Patrick DalyAnemia | October 30, 2023
Plasma thrombopoietin was significantly higher in aplastic anemia and myelodysplastic syndromes compared with control values.
Advertisement
Advertisement
Advertisement
Latest News

July 12, 2024